Compare BioNTech SE - ADR (BNTX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Texas Instruments Incorporated — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Texas Instruments Incorporated trades at $309.97 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 12.2× BioNTech SE - ADR's market cap, and Texas Instruments Incorporated pays a 1.86% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TXN | |
|---|---|---|
Market Cap | $22.86B | $278.08B |
Sector | Health | Technology |
52-Week High | $119.34 | $332.35 |
52-Week Low | $83.89 | $153.33 |
Enterprise Value | $6.53B | $287.03B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Texas Instruments (TXN) trades at $305.55, down 1.91% with a bearish technical signal. The company shows improving fundamentals with Q1 2026 earnings beat ($1.68 vs $1.36 expected) and revenue growth to $17.68B in 2025. Recent CFO transition to Julie Knecht and strong AI-related demand from data centers provide positive catalysts. Valuation remains elevated with P/E of 51.04 and P/S of 14.78, while maintaining strong profitability with 29.11% net margin and 32.18% ROE.
TXN presents a mixed outlook with solid fundamentals offset by premium valuation. The stock offers exposure to growing AI infrastructure demand and operational improvements, but faces risks from competitive pressures and debt levels. Analyst consensus leans bullish with $317.20 price target, though technical indicators suggest near-term caution. The current price near pivot point resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
